StockNews.com Begins Coverage on Bellerophon Therapeutics (NASDAQ:BLPH)

StockNews.com assumed coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPHFree Report) in a report published on Saturday. The brokerage issued a hold rating on the biotechnology company’s stock.

Bellerophon Therapeutics Price Performance

BLPH opened at $0.05 on Friday. Bellerophon Therapeutics has a 1-year low of $0.03 and a 1-year high of $12.58. The company’s 50 day simple moving average is $0.05 and its two-hundred day simple moving average is $0.19. The firm has a market capitalization of $623,730.00, a price-to-earnings ratio of -0.06 and a beta of 0.68.

Bellerophon Therapeutics (NASDAQ:BLPHGet Free Report) last announced its quarterly earnings data on Tuesday, November 14th. The biotechnology company reported ($0.16) earnings per share for the quarter.

Institutional Investors Weigh In On Bellerophon Therapeutics

Several large investors have recently bought and sold shares of the stock. Perceptive Advisors LLC acquired a new position in shares of Bellerophon Therapeutics during the first quarter worth about $7,338,000. Geode Capital Management LLC grew its stake in shares of Bellerophon Therapeutics by 49.0% during the first quarter. Geode Capital Management LLC now owns 95,656 shares of the biotechnology company’s stock worth $755,000 after purchasing an additional 31,460 shares in the last quarter. Renaissance Technologies LLC raised its stake in Bellerophon Therapeutics by 13.0% in the second quarter. Renaissance Technologies LLC now owns 209,399 shares of the biotechnology company’s stock valued at $258,000 after buying an additional 24,100 shares in the last quarter. State Street Corp lifted its holdings in Bellerophon Therapeutics by 41.3% during the 1st quarter. State Street Corp now owns 30,127 shares of the biotechnology company’s stock worth $238,000 after buying an additional 8,800 shares during the last quarter. Finally, Dimensional Fund Advisors LP purchased a new stake in Bellerophon Therapeutics during the 1st quarter worth about $107,000. Hedge funds and other institutional investors own 28.88% of the company’s stock.

Bellerophon Therapeutics Company Profile

(Get Free Report)

Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.

Featured Articles

Receive News & Ratings for Bellerophon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.